



January 26, 2024

Lisa Vershave
Regulatory Affairs Manager
Revvity, Inc.
940 Winter Street
Waltham, MA 02451

Device: Respiratory SARS-CoV-2 RT-PCR Panel 1

EUA Number: EUA202791

Company: Revvity, Inc.

Indication: This test is authorized for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B and/or respiratory syncytial virus (RSV) nucleic acid from nasopharyngeal swabs, anterior nasal swabs, and mid-turbinate swabs, collected from individuals suspected by a healthcare provider of having respiratory viral infection consistent with COVID-19.

Emergency use of this test is limited to authorized laboratories.

Authorized Laboratories: Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform high complexity tests.

Dear Ms. Vershave:

On October 6, 2021, based on PerkinElmer, Inc.'s request, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the PKamp Respiratory SARS-CoV-2 RT-PCR Panel 1 pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3) for the indication stated in the letter.¹ Based on PerkinElmer, Inc.'s requests, FDA granted updates to the authorized labeling on November 1, 2021,² December 14, 2021,³ January 21, 2022,⁴ and July 21, 2022.⁵

¹ The October 6, 2021, letter authorized the PKamp Respiratory SARS-CoV-2 RT-PCR Panel 1 for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B and/or respiratory syncytial virus (RSV) nucleic acid from nasopharyngeal swabs, anterior nasal swabs, and mid-turbinate swabs, collected from individuals suspected by a healthcare provider of having respiratory viral infection consistent with COVID-19. Testing was limited to laboratories certified under CLIA, 42 U.S.C. §263a, that meet requirements to perform high complexity tests.

² On November 1, 2021, PerkinElmer, Inc.'s request was granted to update the Instructions for Use (IFU) of your

On January 18, 2024, you⁶ requested to further revise your Emergency Use Authorization (EUA). Based on this request, and having concluded that revising the October 6, 2021, EUA is appropriate to protect the public health or safety under section 564(g)(2)(C) of the Act (21 U.S.C. § 360bbb-3(g)(2)(C)), FDA is reissuing the October 6, 2021, letter in its entirety with the revisions incorporated.⁷ Pursuant to section 564 of the Act and the Scope of Authorization (Section II) and Conditions of Authorization (Section IV) of this reissued letter, your product⁸ is now authorized for use consistent with the indication described above.

On February 4, 2020, as amended on March 15, 2023, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency, or a significant potential for a public health emergency, that affects, or that has a significant potential to affect, national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19. Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 subject to the terms of any authorization issued under Section 564(a) of the Act.⁹

FDA considered the totality of scientific information available in authorizing the emergency use of your product for the indication above. A summary of the performance information FDA

product to add three additional RT-PCR instruments (QuantStudio Dx 96 and the Analytik Jena qTower platforms (both 96 and 384-well versions)) for use with the PKamp Respiratory SARS-CoV-2 RT-PCR Panel 1 test.

³ On December 14, 2021, PerkinElmer, Inc.'s request was granted to update the Instructions for Use (IFU) of your product to update the reagent stability claim from 12 to 24 months.

⁴ On January 21, 2022, PerkinElmer, Inc.'s request was granted to update the Instructions for Use (IFU) of your product to: (1) update inclusivity study data to fulfill Condition Q. of the October 6, 2021 letter, (2) update interference study data to fulfill Condition P. of the October 6, 2021 letter, (3) update the Limitations section as a result of the new data, and (4) provide minor edits.

⁵ On July 21, 2022, PerkinElmer, Inc.'s request was granted to update the Instructions for Use (IFU) of your product to: (1) update the clinical performance section with results from the prospective clinical study performed to fulfill Condition of Authorization R. of the October 6, 2021 letter, and (2) provide minor edits. In addition, FDA updated the Healthcare Provider and Patient Fact Sheets to reflect more recent authorizations.

⁶ For ease of reference, this letter will use the term “you” and related terms to refer to Revvity, Inc.

⁷ The revisions to the October 6, 2021, letter and authorized labeling include: (1) updating ownership of the EUA from PerkinElmer, Inc. to Revvity, Inc. due to company rebranding, (2) updating the name of the EUA device from “PKamp Respiratory SARS-CoV-2 RT-PCR Panel 1” to “Respiratory SARS-CoV-2 RT-PCR Panel 1,” (3) updating the manufacturing site for the EUA device, (4) removed Conditions of Authorization P., Q., and R. in the October 6, 2021 Letter of Authorization as fulfilled based on data and information provided to FDA, and (5) updating the Fact Sheet for Healthcare Providers and the Letter of Authorization to reflect the updates made and for consistency with language used in more recent authorizations.

⁸ For ease of reference, this letter will use the term “your product” to refer to the Respiratory SARS-CoV-2 RT-PCR Panel 1, used for the indication identified above.

⁹ U.S. Department of Health and Human Services, *Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3*. February 4, 2020. 85 FR 7316 (February 7, 2020). U.S. Department of Health and Human Services, *Amended Determination of a Public Health Emergency or Significant Potential for a Public Health Emergency Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)*. March 15, 2023. 88 FR 16644 (March 20, 2023) (“Amended Determination”).

relied upon is contained in the “Instructions for Respiratory SARS-CoV-2 RT-PCR Panel 1” Instructions for Use (IFU) (identified below). There are a few FDA-approved/cleared test for the qualitative detection and identification of SARS-CoV-2, influenza A, influenza B, and RSV viruses, along in some cases with some other organism types and subtypes not targeted by your product, but they are not adequate and available alternatives to your product. Respiratory viral infections caused by the influenza A, influenza B, RSV, and SARS-CoV-2 viruses can have similar clinical presentation and diagnostic considerations. Thus, to differentially detect SARS-CoV-2 information from a test that detects and differentiates the virus that causes COVID-19 and other common respiratory pathogens, including RSV and the influenza viruses that cause seasonal epidemics of flu, is needed during the flu season that coincides with the COVID-19 pandemic.

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am authorizing the emergency use of your product, described in the Scope of Authorization of this letter (Section II), subject to the terms of this authorization.

I. Criteria for Issuance of Authorization

I have concluded that the emergency use of your product meets the criteria for issuance of an authorization under Section 564(c) of the Act, because I have concluded that:

1. The SARS-CoV-2 can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus;
2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, through the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B, and/or RSV virus RNA, and that the known and potential benefits of your product when used for diagnosing COVID-19, outweigh the known and potential risks of your product; and
3. There is no adequate, approved, and available alternative to the emergency use of your product.¹⁰

II. Scope of Authorization

I have concluded, pursuant to Section 564(d)(1) of the Act, that the scope of this authorization is limited to the indication above.

Authorized Product Details

Your product is a real-time RT-PCR multiplexed test intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B and/or respiratory syncytial virus (RSV) nucleic acid from nasopharyngeal swabs, anterior nasal swabs, and mid-turbinate swabs, collected from individuals suspected by a healthcare provider of having

¹⁰ No other criteria of issuance have been prescribed by regulation under Section 564(c)(4) of the Act.

respiratory viral infection consistent with COVID-19. Symptoms of respiratory viral infection due to SARS-CoV-2, influenza, and RSV can be similar.

Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet requirements to perform high complexity tests.

Your product is intended for use in the detection and differentiation of SARS-CoV-2, influenza A, influenza B, and/or RSV viral RNA in patient specimens, and is not intended to detect influenza C. RNA from SARS-CoV-2, influenza A, influenza B, and RSV viruses is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results are indicative of active infection but do not rule out bacterial infection or coinfection with other viruses not detected by the test; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. The agent detected may not be the definitive cause of disease. Negative results do not preclude SARS-CoV-2, influenza A, influenza B, and/or RSV infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and/or epidemiological information.

To use your product, SARS-CoV-2 nucleic acid is first extracted, isolated and purified from nasopharyngeal swab, anterior nasal swab, and mid-turbinate swab specimens, as described in the “Instructions for Respiratory SARS-CoV-2 RT-PCR Panel 1” IFU. The purified nucleic acid is then reverse transcribed into cDNA followed by PCR amplification and detection using an authorized real-time (RT) PCR instrument, as described in the “Instructions for Respiratory SARS-CoV-2 RT-PCR Panel 1” IFU. Your product includes the materials (or other authorized materials as may be requested under Condition K. Below) described in the “Instructions for Respiratory SARS-CoV-2 RT-PCR Panel 1” IFU.

Your product requires control materials (or other authorized control materials as may be requested under Condition K. below), that are to be run as outlined in the “Instructions for Respiratory SARS-CoV-2 RT-PCR Panel 1” IFU.

Your product also requires the use of additional authorized materials and authorized ancillary reagents that are not included with your product and are described in the “Instructions for Respiratory SARS-CoV-2 RT-PCR Panel 1” IFU.

The labeling entitled “Instructions for Respiratory SARS-CoV-2 RT-PCR Panel 1” IFU (available at <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas>) and the following fact sheets pertaining to the emergency use, are required to be made available as set forth in the Conditions of Authorization (Section IV), and are collectively referred to as “authorized labeling”:

- Fact Sheet for Healthcare Providers: Revvity, Inc. - Respiratory SARS-CoV-2 RT-PCR Panel 1
- Fact Sheet for Patients: Revvity, Inc. - Respiratory SARS-CoV-2 RT-PCR Panel 1

The above described product, when accompanied by the authorized labeling provided as set forth in the Conditions of Authorization (Section IV), is authorized to be distributed to and used by authorized laboratories under this EUA, despite the fact that it does not meet certain requirements otherwise required by applicable federal law.

I have concluded, pursuant to Section 564(d)(2) of the Act, that it is reasonable to believe that the known and potential benefits of your product, when used consistent with the Scope of Authorization of this letter (Section II), outweigh the known and potential risks of your product.

I have concluded, pursuant to Section 564(d)(3) of the Act, based on the totality of scientific evidence available to FDA, that it is reasonable to believe that your product may be effective in diagnosing COVID-19, through the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A virus, influenza B, and/or RSV virus RNA, when used consistent with the Scope of Authorization of this letter (Section II), pursuant to Section 564(c)(2)(A) of the Act.

FDA has reviewed the scientific information available to FDA, including the information supporting the conclusions described in Section I above, and concludes that your product (as described in the Scope of Authorization of this letter (Section II)) meets the criteria set forth in Section 564(c) of the Act concerning safety and potential effectiveness.

The emergency use of your product under this EUA must be consistent with, and may not exceed, the terms of this letter, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section IV). Subject to the terms of this EUA and under the circumstances set forth in the Secretary of HHS's determination under Section 564(b)(1)(C) of the Act described above and the Secretary of HHS's corresponding declaration under Section 564(b)(1) of the Act, your product is authorized for the indication above.

III. Waiver of Certain Requirements

I am waiving the following requirements for your product during the duration of this EUA:

- Current good manufacturing practice requirements, including the quality system requirements under 21 CFR Part 820 with respect to the design, manufacture, packaging, labeling, storage, and distribution of your product, but excluding Subpart H (Acceptance Activities, 21 CFR 820.80 and 21 CFR 820.86), Subpart I (Nonconforming Product, 21 CFR 820.90), and Subpart O (Statistical Techniques, 21 CFR 820.250).

IV. Conditions of Authorization

Pursuant to Section 564(e) of the Act, I am establishing the following conditions on this authorization:

Revvity, Inc. (You) and Authorized Distributor(s)¹¹

- A. Your product must comply with the following labeling requirements pursuant to FDA regulations: the intended use statement (21 CFR 809.10(a)(2), (b)(2)); adequate directions for use (21 U.S.C. 352(f)), (21 CFR 809.10(b)(5), (7), and (8)); appropriate limitations on the use of the device including information required under 21 CFR 809.10(a)(4); and any available information regarding performance of the device, including requirements under 21 CFR 809.10(b)(12).
- B. You and authorized distributor(s) must make your product available with the authorized labeling to authorized laboratories.
- C. You and authorized distributor(s) must make available on your website(s) the authorized labeling.
- D. You and authorized distributor(s) must include a physical copy of the “Instructions for Respiratory SARS-CoV-2 RT-PCR Panel 1” IFU with each shipped product to authorized laboratories.
- E. You and authorized distributor(s) must inform authorized laboratories and relevant public health authorities of this EUA, including the terms and conditions herein, and any updates made to your product and authorized labeling.
- F. Through a process of inventory control, you and authorized distributor(s) must maintain records of the authorized laboratories to which they distribute your product and number they distribute.
- G. You and authorized distributor(s) must collect information on the performance of your product. You will report to FDA any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of the product of which you become aware.
- H. You and authorized distributor(s) are authorized to make available additional information relating to the emergency use of your product that is consistent with, and does not exceed, the terms of this letter of authorization.

Revvity, Inc. (You)

- I. You must notify FDA of any authorized distributor(s) of your product, including the name, address, and phone number of any authorized distributor(s).

¹¹ “Authorized Distributor(s)” are identified by you, Revvity, Inc., in your EUA submission as an entity allowed to distribute your product.

- J. You must provide authorized distributor(s) with a copy of this EUA and communicate to authorized distributor(s) any subsequent amendments that might be made to this EUA and its authorized accompanying materials (e.g., Fact Sheets).
- K. You may request changes to this EUA for your product, including to the Scope of Authorization (Section II in this letter) or to the authorized labeling, including requests to make available additional authorized labeling specific to an authorized distributor. Such additional labeling may use another name for the product but otherwise must be consistent with the authorized labeling, and not exceed the terms of authorization of this letter. Any request for changes to this EUA should be submitted to the Division of Microbiology (DMD)/Office of Health Technology 7 (OHT7)/Office of Product Evaluation and Quality (OPEQ)/Center for Devices and Radiological Health (CDRH) and require appropriate authorization from FDA prior to implementation.
- L. You must comply with the following requirements pursuant to FDA regulations: 21 CFR 820 Subpart H (Acceptance Activities, 21 CFR 820.80 and 21 CFR 820.86), Subpart I (Nonconforming Product, 21 CFR 820.90), and Subpart O (Statistical Techniques, 21 CFR 820.250).
- M. You must have lot release procedures and the lot release procedures, including the study design and statistical power, must ensure that the tests released for distribution have the clinical and analytical performance claimed in the authorized labeling.
- N. If requested by FDA, you must submit lot release procedures to FDA, including sampling protocols, testing protocols, and acceptance criteria, that you use to release lots of your product for distribution in the U.S. If such lot release procedures are requested by FDA, you must provide it within 48 hours of the request.
- O. You must evaluate the analytical limit of detection and assess traceability¹² of your product with any FDA-recommended reference material(s) if requested by FDA. After submission to and concurrence with the data by FDA, you must update your labeling to reflect the additional testing if requested by FDA. Such labeling updates will be made in consultation with, and require concurrence of, DMD/OHT7/OPEQ/CDRH.
- P. You must have a process in place to track adverse events, including any occurrence of false results with your product and report to FDA pursuant to 21 CFR Part 803.
- Q. You must evaluate the impact of SARS-CoV-2 viral mutations and all other target analytes on your product's performance. Such evaluations must occur on an ongoing basis and must include any additional data analysis that is requested by FDA in response to any performance concerns you or FDA identify during routine evaluation. Additionally, if requested by FDA, you must submit records of these evaluations for FDA review within 48 hours of the request. If your evaluation identifies viral mutations

¹² Traceability refers to tracing analytical sensitivity/reactivity back to an FDA-recommended reference material.

that affect the stated expected performance of your device, you must notify FDA immediately.

- R. If requested by FDA, you must update your labeling within 7 calendar days to include any additional labeling risk mitigations identified by FDA, such as those related to the impact of viral mutations on test performance. Such updates will be made in consultation with, and require concurrence of, DMD/OHT7/OPEQ/CDRH.

Authorized Laboratories

- S. Authorized laboratories using your product must include with test result reports, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.
- T. Authorized laboratories using your product must use your product as outlined in the authorized labeling. Deviations from the authorized procedures, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and authorized materials required to use your product are not permitted.
- U. Authorized laboratories that receive your product must notify the relevant public health authorities of their intent to run your product prior to initiating testing.
- V. Authorized laboratories using your product must have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.
- W. Authorized laboratories must collect information on the performance of your product and report to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov) and Revvity COVID-19 Technical Support (via email: COVID-19TechnicalSupport@Revvity.com and US Toll-Free: 1-888-208-2246) any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of your product of which they become aware.
- X. All laboratory personnel using this product must be appropriately trained in RT-PCR techniques, the specific processes and instruments used in the Respiratory SARS-CoV-2 RT-PCR Panel 1 and use appropriate laboratory and personal protective equipment when handling this kit, and use this product in accordance with the authorized labeling.

Revvity, Inc. (You), Authorized Distributor(s) and Authorized Laboratories

- Y. You, authorized distributor(s), and authorized laboratories using your product will ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

Conditions Related to Printed Materials, Advertising and Promotion

- Z. All descriptive printed matter, advertising and promotional materials relating to the use of your product shall be consistent with the authorized labeling, as well as the terms set forth in this EUA and meet the requirements set forth in section 502(a), (q)(1), and (r) of the Act, as applicable, and FDA implementing regulations.
- AA. No descriptive printed matter, advertising or promotional materials relating to the use of your product may represent or suggest that this test is safe or effective for the detection of SARS-CoV-2.
- BB. All descriptive printed matter, advertising and promotional materials relating to the use of your product shall clearly and conspicuously state that:
- This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
 - This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV) not for any other viruses or pathogens; and
 - The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

The emergency use of your product as described in this letter of authorization must comply with the conditions and all other terms of this authorization.

V. Duration of Authorization

This EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 is terminated under Section 564(b)(2) of the Act or the EUA is revoked under Section 564(g) of the Act.

Sincerely,

Jeffrey E. Shuren, M.D., J.D.
Director
Center for Devices and Radiological Health
Food and Drug Administration

Enclosure